## TFMB-(R)-2-HG

HY-129079			
1445700-01-5			
$C_{13}H_{11}F_{3}O_{4}$			
288			
Others			
Others			
Powder	-20°C	3 years	
In solvent	-80°C	6 months	
	-20°C	1 month	
	1445700-01 C <sub>13</sub> H <sub>11</sub> F <sub>3</sub> O <sub>4</sub> 288 Others Others Powder	$1445700-01-5$ $C_{13}H_{11}F_{3}O_{4}$ 288         Others         Others         Powder       -20°C         In solvent       -80°C	

### SOLVENT & SOLUBILITY

	Conce Preparing Stock Solutions	Solvent Concentration	1 mg	5 mg	10 mg
		1 mM	3.4722 mL	17.3611 mL	34.7222 mL
		5 mM	0.6944 mL	3.4722 mL	6.9444 mL
		10 mM	0.3472 mL	1.7361 mL	3.4722 mL
	Please refer to the solu	bility information to select the ap	propriate solvent.		
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.22 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.22 mM); Clear solution				

BIOLOGICAL ACTIVITY				
Description	TFMB-(R)-2-HG, a cell membrane-permeable version of (R)-2-HG, is a carcinogenic factor in Acute myeloid leukemia (AML).TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cells differentiation in response to estrogen withdrawal <sup>[1]</sup> .			
IC <sub>50</sub> & Target	Carcinogenic factor <sup>[1]</sup>			

#### REFERENCES

# Product Data Sheet

0=

F K F



[1]. Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA